CyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical use Noninvasive test has potential to transform lung cancer risk assessment and nodule management SAN ANTONIO, TX – May 12, 2026 – bioAffinity Technologies, Inc. (Nasdaq: […]
CyPath® Lung cancer diagnostic unit sales rise 146% year-over-year Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung benefits SAN ANTONIO, TX – May 8, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the […]
Collaboration with nation’s largest military medical center focuses on bioAffinity Technologies’ pipeline of solutions to address debilitating respiratory diseases Study to explore the potential for proprietary flow cytometry+AI diagnostic tests targeting the asthma and COPD treatment market estimated at $92 billion[1] SAN ANTONIO, TX – April 28, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), […]
Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed physician’s assessment that the nodule could be inflammation, not cancer; nodule resolved upon follow-up scan Noninvasive CyPath® Lung performed with 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in more difficult to diagnose small nodules […]
Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, to participate in panel on lung nodule management SAN ANTONIO, TX – April 7, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused […]
Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI technology has potential to improve lung cancer risk assessment and nodule management SAN ANTONIO, TX – April 1, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), […]